Clinical Trials
9 trialsNCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed
NCT04761614 2025-03-28
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03396926 2025-02-28
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Phase 2 Completed
NCT04164069 2024-12-27
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02754856 2024-10-09
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02873195 2024-08-23
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT02292758 2022-01-31
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT02164916 2020-12-30
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT03005002 2019-12-26
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
City of Hope Medical Center
Phase 1 Completed